



## **Quidel to Hold 2008 First Quarter Conference Call on April 23, 2008**

April 9, 2008

SAN DIEGO--(BUSINESS WIRE)--April 9, 2008--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, will release 2008 first quarter financial results after market close on Wednesday, April 23, 2008.

Following the release of the results, Caren L. Mason, president and chief executive officer, and John M. Radak, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. ET (2:00 p.m. PT) to discuss those results and to answer questions.

To participate in the live call by telephone from the U.S., dial (888) 713-4209, or from outside the U.S. dial (617) 213-4863, and enter the passcode 13480657. Callers can use the following link to pre-register for this conference call: <https://www.theconferencingservice.com/prereg/key.process?key=PR9CWJ4LG>.

A live webcast of the call can be accessed at [www.quidel.com](http://www.quidel.com), and the Web site replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 7:00 p.m. ET (4:00 p.m. PT) on April 23 by dialing (888) 286-8010 from the U.S., or (617) 801-6888 for international callers, and entering passcode 24010350.

### About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment have an impact on clinical outcomes and provide an economic benefit. For more information, visit [www.quidel.com](http://www.quidel.com), [www.colorectal-test.com](http://www.colorectal-test.com) or [www.flutest.com](http://www.flutest.com).

NOTE: Long URLs in this release may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.

CONTACT: Quidel Corporation  
John M. Radak, Chief Financial Officer  
858-646-8032  
or  
Porter Novelli Life Sciences  
Rachel Lipsitz  
619-849-5378  
[rlipsitz@pnlifesciences.com](mailto:rlipsitz@pnlifesciences.com)

SOURCE: Quidel Corporation